CNS Pharmaceuticals (NASDAQ:CNSP) Releases Quarterly Earnings Results, Misses Estimates By $4.78 EPS

CNS Pharmaceuticals (NASDAQ:CNSP) issued its quarterly earnings results on Monday. The company reported ($10.15) EPS for the quarter, missing analysts’ consensus estimates of ($5.37) by ($4.78), FiscalAI reports.

CNS Pharmaceuticals Trading Up 0.4%

CNSP stock opened at $2.40 on Wednesday. The firm has a 50-day moving average of $3.66 and a two-hundred day moving average of $6.10. The firm has a market capitalization of $1.49 million, a PE ratio of -0.08 and a beta of 2.70. CNS Pharmaceuticals has a one year low of $2.06 and a one year high of $34.80.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $20.00.

Hedge Funds Weigh In On CNS Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in CNSP. Boothbay Fund Management LLC acquired a new stake in shares of CNS Pharmaceuticals in the 4th quarter valued at $71,000. Ikarian Capital LLC bought a new stake in shares of CNS Pharmaceuticals during the 4th quarter worth about $241,000. Finally, Armistice Capital LLC bought a new position in shares of CNS Pharmaceuticals in the 2nd quarter valued at approximately $335,000. 14.02% of the stock is currently owned by hedge funds and other institutional investors.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.